ATE425965T1 - 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen - Google Patents

1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen

Info

Publication number
ATE425965T1
ATE425965T1 AT04734774T AT04734774T ATE425965T1 AT E425965 T1 ATE425965 T1 AT E425965T1 AT 04734774 T AT04734774 T AT 04734774T AT 04734774 T AT04734774 T AT 04734774T AT E425965 T1 ATE425965 T1 AT E425965T1
Authority
AT
Austria
Prior art keywords
tetrasubstituted
indole
treatment
respiratory diseases
respiratory
Prior art date
Application number
AT04734774T
Other languages
German (de)
English (en)
Inventor
Roger Bonnert
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE425965T1 publication Critical patent/ATE425965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04734774T 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen ATE425965T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds

Publications (1)

Publication Number Publication Date
ATE425965T1 true ATE425965T1 (de) 2009-04-15

Family

ID=33492578

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08165755T ATE502010T1 (de) 2003-05-27 2004-05-25 Verwendung von 3-phenylthio-1h-indol-1-essigsäure-derivate als modulatoren der crth2-rezeptor- aktivität
AT04734774T ATE425965T1 (de) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
AT10180348T ATE552243T1 (de) 2003-05-27 2004-05-25 4-(acetylamino)-3-ä(4-chlorophenyl)thioü-2-meth l-1h-indole-1-essigsäure-ethyl-ester zwischenverbindung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08165755T ATE502010T1 (de) 2003-05-27 2004-05-25 Verwendung von 3-phenylthio-1h-indol-1-essigsäure-derivate als modulatoren der crth2-rezeptor- aktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10180348T ATE552243T1 (de) 2003-05-27 2004-05-25 4-(acetylamino)-3-ä(4-chlorophenyl)thioü-2-meth l-1h-indole-1-essigsäure-ethyl-ester zwischenverbindung

Country Status (30)

Country Link
US (4) US7687535B2 (enExample)
EP (3) EP1656346B1 (enExample)
JP (2) JP4541361B2 (enExample)
KR (3) KR20110050754A (enExample)
CN (2) CN102391171A (enExample)
AR (1) AR044552A1 (enExample)
AT (3) ATE502010T1 (enExample)
AU (1) AU2004242624B2 (enExample)
BR (1) BRPI0410711B8 (enExample)
CA (1) CA2526866C (enExample)
CO (1) CO5630030A2 (enExample)
CY (3) CY1109104T1 (enExample)
DE (2) DE602004020072D1 (enExample)
DK (3) DK2281815T3 (enExample)
ES (3) ES2361485T3 (enExample)
HR (3) HRP20090281T1 (enExample)
IL (4) IL171928A (enExample)
IS (2) IS2722B (enExample)
MX (1) MXPA05012680A (enExample)
MY (1) MY144483A (enExample)
NO (1) NO20056130L (enExample)
NZ (1) NZ543722A (enExample)
PL (3) PL2025670T3 (enExample)
PT (3) PT1656346E (enExample)
RU (1) RU2361860C2 (enExample)
SE (2) SE0301569D0 (enExample)
SI (3) SI2025670T1 (enExample)
TW (2) TWI328004B (enExample)
WO (1) WO2004106302A1 (enExample)
ZA (1) ZA200509598B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
BRPI0508540B8 (pt) 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
BRPI0519280A2 (pt) 2004-12-27 2009-01-06 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
KR101380448B1 (ko) 2005-04-21 2014-04-11 메르크 세로노 에스. 에이. ２，３치환된 피라진 술폰아미드
DK1891075T3 (da) 2005-05-24 2011-12-19 Merck Serono Sa Tricykliske spiroderivater som CRTH2-modulatorer
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
ES2399061T3 (es) * 2005-09-30 2013-03-25 Pulmagen Therapeutics (Asthma) Limited Quinolinas y su uso terapéutico
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
PT2037967T (pt) 2006-06-16 2017-03-14 Univ Pennsylvania Antagonistas do recetor de prostaglandina d2 para o tratamento da alopecia androgenética
EP2492268A1 (en) * 2006-07-22 2012-08-29 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2051962E (pt) 2006-08-07 2012-01-10 Actelion Pharmaceuticals Ltd Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
MY149005A (en) * 2007-06-21 2013-06-28 Actimis Pharmaceuticals Inc Amine salts of a crth2 antagonist
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
CN102482214B (zh) * 2009-07-06 2014-08-27 阿斯利康(瑞典)有限公司 制备4-(乙酰基氨基)-3-[(4-氯-苯基)硫基]-2-甲基-1h-吲哚-1-乙酸的中间体和方法
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
PH12012501863A1 (en) 2010-03-22 2021-06-23 Idorsia Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
UA110245C2 (xx) 2011-04-14 2015-12-10 Actelion Pharmaceuticals Ltd ПОХІДНІ 7-(ГЕТЕРОАРИЛАМІНО)-6,7,8,9-ТЕТРАГІДРОПІРИДО$1,2-а]ІНДОЛ-ОЦТОВОЇ КИСЛОТИ ТА ЇХ ЗАСТОСУВАННЯ ЯК МОДУЛЯТОРІВ РЕЦЕПТОРА ПРОСТАГЛАНДИНУ D2
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
CN108938441A (zh) 2012-03-21 2018-12-07 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
JP6496246B2 (ja) * 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
RU2680100C9 (ru) * 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014190199A1 (en) * 2013-05-24 2014-11-27 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
US12493355B2 (en) 2022-04-14 2025-12-09 Kohler Co. Touchless plumbing control system

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
EP0686148A4 (en) 1993-02-24 1996-02-07 Merck & Co Inc INHIBITORS OF HIV INVERSE TRANSCRIPTASE
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
ES2198033T3 (es) 1997-12-19 2004-01-16 Eli Lilly And Company Compuestos de imidazolina hipoglucemicos.
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
NZ519121A (en) 1999-12-24 2004-05-28 Aventis Pharma Ltd Azaindoles useful as Syk kinase inhibitors
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
NZ522861A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
JP2004504391A (ja) 2000-07-07 2004-02-12 アンギオジェン・ファーマシューティカルズ・リミテッド 血管新生阻害剤としてのコルキノール誘導体
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
KR100656037B1 (ko) 2002-02-01 2006-12-11 에프. 호프만-라 로슈 아게 알파-1 작용제인 치환된 인돌
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
EP1675826A1 (en) 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
JP2009539782A (ja) 2006-06-08 2009-11-19 ニューロキー エイ／エス 低体温誘導薬剤の使用方法
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.

Also Published As

Publication number Publication date
AU2004242624A1 (en) 2004-12-09
IS8189A (is) 2005-12-20
PT1656346E (pt) 2009-05-20
PT2281815E (pt) 2012-05-24
AR044552A1 (es) 2005-09-21
CY1111469T1 (el) 2015-08-05
BRPI0410711B8 (pt) 2021-05-25
KR101067586B1 (ko) 2011-09-27
CN102391171A (zh) 2012-03-28
ES2361485T3 (es) 2011-06-17
EP1656346B1 (en) 2009-03-18
DE602004020072D1 (de) 2009-04-30
TW200510301A (en) 2005-03-16
PL2025670T3 (pl) 2011-07-29
CA2526866C (en) 2012-10-16
BRPI0410711B1 (pt) 2018-09-25
HK1126773A1 (en) 2009-09-11
IL212265A0 (en) 2011-06-30
HK1149563A1 (en) 2011-10-07
IS8920A (is) 2010-08-09
KR20060015303A (ko) 2006-02-16
TW201024261A (en) 2010-07-01
IL194872A0 (en) 2011-08-01
PT2025670E (pt) 2011-05-24
CN1795174B (zh) 2011-09-28
IL212371A0 (en) 2011-06-30
PL2281815T3 (pl) 2012-08-31
ES2322650T3 (es) 2009-06-24
EP1656346A1 (en) 2006-05-17
EP2281815A1 (en) 2011-02-09
SI2025670T1 (sl) 2011-06-30
HRP20120390T1 (hr) 2012-06-30
ZA200509598B (en) 2006-12-27
TWI328004B (en) 2010-08-01
JP4541361B2 (ja) 2010-09-08
NO20056130L (no) 2006-02-27
ATE552243T1 (de) 2012-04-15
AU2004242624B2 (en) 2008-03-13
US20080249110A1 (en) 2008-10-09
IS2722B (is) 2011-03-15
IL171928A0 (en) 2006-04-10
IL171928A (en) 2011-06-30
JP2007501269A (ja) 2007-01-25
ATE502010T1 (de) 2011-04-15
US20110263614A1 (en) 2011-10-27
JP2010155862A (ja) 2010-07-15
WO2004106302A1 (en) 2004-12-09
DK1656346T3 (da) 2009-06-15
DK2025670T3 (da) 2011-06-06
MXPA05012680A (es) 2006-02-08
SI2281815T1 (sl) 2012-06-29
KR20110050754A (ko) 2011-05-16
US20090163518A1 (en) 2009-06-25
US7687535B2 (en) 2010-03-30
US20120178764A1 (en) 2012-07-12
SI1656346T1 (sl) 2009-08-31
BRPI0410711A (pt) 2006-06-13
CO5630030A2 (es) 2006-04-28
HK1090635A1 (zh) 2006-12-29
EP2281815B1 (en) 2012-04-04
NZ543722A (en) 2007-05-31
EP2025670B1 (en) 2011-03-16
SE0301569D0 (sv) 2003-05-27
DE602004031894D1 (de) 2011-04-28
CN1795174A (zh) 2006-06-28
PL1656346T3 (pl) 2009-07-31
EP2025670A1 (en) 2009-02-18
CY1112853T1 (el) 2016-02-10
MY144483A (en) 2011-09-30
RU2361860C2 (ru) 2009-07-20
CY1109104T1 (el) 2014-07-02
KR20110051297A (ko) 2011-05-17
CA2526866A1 (en) 2004-12-09
SE0302305D0 (sv) 2003-08-27
KR101067535B1 (ko) 2011-09-27
DK2281815T3 (da) 2012-06-18
RU2005137403A (ru) 2006-05-27
HRP20090281T1 (hr) 2009-06-30
HRP20110359T1 (hr) 2011-06-30
ES2382606T3 (es) 2012-06-11

Similar Documents

Publication Publication Date Title
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
EP1491212A4 (en) REMEDY AGAINST SLEEP DISORDERS
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE60130691D1 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
DE602004010172D1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE345137T1 (de) Verwendung von 2h-(1,3)-oxazino(3,2-a)indol- derivaten zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1656346

Country of ref document: EP